All In Biotech

Drug Trial Radar · NCT06380699

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single and Multiple Doses

Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Mar 16, 2023

Primary completion

Nov 16, 2023

Study completion Dec 25, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.

Conditions

  • Acute Ischemic Stroke

Interventions

  • QHRD106 InjectionDrug

    PEG-tissue kallikrein-1

  • Human Urinary KallidinogenaseDrug

    tissue kallikrein-1

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as assessed by incidence, severity, and causality of adverse eventsTime frame: Up to 43 days after final dose
  2. Plasma measurements of QHRD106Time frame: Up to 43 days after final dose
  3. Concentration of bradykinin in plasmaTime frame: Up to 43 days after final dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.